CheckMan Stock Market Overview

Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.

New York, New York--(Newsfile Corp. - October 7, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of AST SpaceMobile, Inc. (NASDAQ: ASTS) between March 4, 2025 and July 15, 2026, inclusive (the "Class Period"), of the important November 13, 2026 lead plaintiff deadline. SO WHAT: If you purchased AST SpaceMobile securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

Reblozyl's strong growth is helping Bristol Myers offset declining legacy drug sales, with new indications offering further upside.

Wells Fargo stock slipped as federal housing officials announced a probe into its mortgage programs aimed at boosting black and minority homeownership.

RESTON, Va., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Stride Inc. (NYSE: LRN) announced today its plans to discuss its first quarter fiscal year 2027 financial results during a conference call scheduled for Tuesday, October 20, 2026 at 5:00 p.m.

COHR's AI-driven optical demand, 1.6T ramp and expanding capacity support its growth case even after an 8% monthly stock gain.

GLW's AI-driven optical growth, major data-center deals and surging solar sales are reshaping its outlook despite valuation and profit risks.

Nokia's AI & Cloud growth and expanding AI networking efforts support its outlook, but cyclical telecom spending and competition remain concerns.

NEW YORK, Oct. 7, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lincoln Educational Services Corporation (NASDAQ: LINC) between May 11, 2026 and August 9, 2026, inclusive (the "Class Period"), of the important November 10, 2026 lead plaintiff deadline. So What: If you purchased Lincoln Educational Services securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP's medicinal chemistry leverages the Y220C mutation to stabilize p53, translating into consistent clinical activity across heavily pretreated patients. Risks include a limited initial market, acquired resistance, significant dilution from recent financings, and pivotal Phase 2 data due in Q4 2026.